Relay Therapeutics, Inc. (RLAY)
| Market Cap | 1.83B |
| Revenue (ttm) | 15.36M |
| Net Income (ttm) | -276.48M |
| Shares Out | 178.73M |
| EPS (ttm) | -1.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,212,545 |
| Open | 9.64 |
| Previous Close | 9.16 |
| Day's Range | 9.40 - 11.43 |
| 52-Week Range | 1.78 - 11.43 |
| Beta | 1.62 |
| Analysts | Strong Buy |
| Price Target | 14.50 (+41.33%) |
| Earnings Date | Feb 26, 2026 |
About RLAY
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the treatment of breast cancer, solid tumor, and vascular malformations; and αGal chaperone for Fabry diseases. It also develops R... [Read more]
Financial Performance
In 2025, Relay Therapeutics's revenue was $15.36 million, an increase of 53.44% compared to the previous year's $10.01 million. Losses were -$276.48 million, -18.13% less than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RLAY stock is "Strong Buy." The 12-month stock price target is $14.5, which is an increase of 41.33% from the latest price.
News
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced i...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib ...
Oppenheimer Upgrade Fuels Relay Therapeutics Rally On Zovegalisib Optimism
Relay Therapeutics is upgraded to Outperform with a $14 price target, driven by optimism for zovegalisib in PIK3CA-mutant HR+/HER2- metastatic breast cancer. Zovegalisib's mutant-selective PI3Kα inhib...
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with P...
Relay Therapeutics, Inc. (RLAY) Presents at Jefferies London Healthcare Conference 2025 Transcript
Relay Therapeutics, Inc. ( RLAY) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate...
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercia...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...
Relay Therapeutics Is A Buy For Its Superb Safety Data
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rates...
Relay Therapeutics, Inc. (RLAY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Relay Therapeutics, Inc. (NASDAQ:RLAY) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Sanjiv Patel - CEO, President & Director Donald Ber...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies ...
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReD...
Relay Therapeutics: What's Next For H2 2025?
Upgraded Relay Therapeutics to a buy after an unjustified valuation decline, maintaining cautious optimism. Recent ASCO data and quarterly updates provide new insights into the evolving investment the...
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-ed...
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edg...
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fu...
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-e...
Relay Therapeutics: Trying To Find That Right Price
Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, sho...
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer